2-cyclopropylimidazo[1,2-a]pyridin-6-amine | 1339201-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-cyclopropylimidazo[1,2-a]pyridin-6-amine
• CAS: 1339201-66-9
• 化学式: C₁₀H₁₁N₃
• 分子量: 173.217
• InChiKey: USWVPWKMZUKXSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-cyclopropylimidazo[1,2-a]pyridin-6-amine 、 4’-三氟甲基-二苯基-4-甲酸 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 N-(2-cyclopropylimidazo[1,2-a]pyridin-6-yl)-4'-(trifluoromethyl)[1,1'-biphenyl]-4-carboxamide
  参考文献：
  名称：

  Discovery of imidazo[1,2-a]pyridines as potent MCH1R antagonists

  摘要：

  A series of imidazo[1,2-a] pyridine derivatives was identified and evaluated for MCH1R binding and antagonistic activity. Introduction of a methyl substituent at the 3-position of imidazo[1,2-a] pyridine provided compounds with a significant improvement in MCH1R affinity. Representative compounds in this series exhibited good potency and brain exposure in rats. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.101
• 作为产物：
  描述：

  2-cyclopropyl-6-nitroimidazo[1,2-a]pyridine 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 18.0h， 生成 2-cyclopropylimidazo[1,2-a]pyridin-6-amine
  参考文献：
  名称：

  IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS

  摘要：

  这项发明涉及Imidazo[1,2-a]pyridinyl Derivatives的化合物（I′）或其药学上可接受的盐，其中所有变量如规范中所定义，能够调节IRAK4的活性。该发明进一步提供了一种制造该发明化合物的方法，以及它们在治疗中的方法。该发明还提供了它们的制备方法，医学用途，特别是在治疗和管理炎症性疾病、自身免疫疾病、癌症、心血管疾病、中枢神经系统疾病、皮肤疾病、眼科疾病和骨骼疾病等疾病或疾病的用途。

  公开号：

  US20220089592A1

文献信息

• IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS
  申请人：BIOGEN MA INC.

  公开号：US20220089592A1

  公开（公告）日：2022-03-24

  This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

  这项发明涉及Imidazo[1,2-a]pyridinyl Derivatives的化合物（I′）或其药学上可接受的盐，其中所有变量如规范中所定义，能够调节IRAK4的活性。该发明进一步提供了一种制造该发明化合物的方法，以及它们在治疗中的方法。该发明还提供了它们的制备方法，医学用途，特别是在治疗和管理炎症性疾病、自身免疫疾病、癌症、心血管疾病、中枢神经系统疾病、皮肤疾病、眼科疾病和骨骼疾病等疾病或疾病的用途。
• [EN] IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINYLE SERVANT D'INHIBITEURS D'IRAK4
  申请人：BIOGEN MA INC

  公开号：WO2020150626A1

  公开（公告）日：2020-07-23

  This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I'), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.
• Discovery of imidazo[1,2-a]pyridines as potent MCH1R antagonists
  作者：Hiroyuki Kishino、Minoru Moriya、Shunji Sakuraba、Toshihiro Sakamoto、Hidekazu Takahashi、Takao Suzuki、Ryuichi Moriya、Masahiko Ito、Hisashi Iwaasa、Norihiro Takenaga、Akane Ishihara、Akio Kanatani、Nagaaki Sato、Takehiro Fukami

  DOI：10.1016/j.bmcl.2009.06.101

  日期：2009.8

  A series of imidazo[1,2-a] pyridine derivatives was identified and evaluated for MCH1R binding and antagonistic activity. Introduction of a methyl substituent at the 3-position of imidazo[1,2-a] pyridine provided compounds with a significant improvement in MCH1R affinity. Representative compounds in this series exhibited good potency and brain exposure in rats. (C) 2009 Elsevier Ltd. All rights reserved.